Tumor biomarker analysis following the fourth relapse revealed a MYCN mutation (c.131C>T resulting in p.Pro44Leu amino acid alteration) and amplification of CDK4, MYCN, ERBB3, GLI1, and FGFR4. No RB1 alterations were detected. The gene discussed is FGFR4; the disease is neoplasm.